Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact
10 Luglio 2024 - 2:30PM
Business Wire
Provides updates on Baxter’s 2030 Corporate
Responsibility Commitment and Goals and reinforces the company’s
commitment to transparent reporting
Baxter International Inc. (NYSE:BAX), a global medtech leader,
today published its 2023 Corporate Responsibility Report. The
annual report showcases Baxter’s dedication to making a meaningful
difference in global healthcare and reporting with transparency on
the environmental, social and governance topics most important to
its stakeholders.
“Baxter employees across the globe are connected by our shared
commitment to doing business the right way and continually driving
a positive impact for the patients, clinicians and communities we
serve,” said José (Joe) E. Almeida, chair, president and chief
executive officer. “As we continue to focus on creating value for
our stakeholders through our 2030 Corporate Responsibility
Commitment and Goals, our approach will remain grounded in our
sustainable business model and central to Baxter’s Mission to Save
and Sustain Lives.”
2023 Corporate Responsibility Highlights
Baxter’s 2023 Corporate Responsibility Report shares updates on
the company’s 2030 Corporate Responsibility Commitment and Goals,
which support an overarching pledge to “Empower our Patients,”
“Protect our Planet” and “Champion our People and Communities.” Key
accomplishments highlighted in the report include:
- Invested more than $143 million since 2021 to support
underserved communities through strategic partnerships and
donations.
- Announced a new partnership with UNICEF and a $2.5 million
commitment through the Baxter International Foundation to improve
climate-smart access to safe drinking water and sanitation in
water-challenged regions of Egypt.
- Completed 150 energy conservation projects in 2023, which are
estimated to reduce greenhouse gas (GHG) emissions by approximately
21,100 metric tons carbon dioxide equivalent per year beginning in
2024. This is nearly double the GHG emissions reduction achieved
with energy projects completed in 2022.1
- Continued to achieve top quartile workplace safety performance,
as measured by total recordable incident rate.
Transparent Reporting on Priority Stakeholder Topics
Building on more than 30 years of reporting on environmental and
sustainability performance, Baxter aims to consistently broaden and
enhance its reporting on the corporate responsibility topics that
matter to its stakeholders. In 2023, the company published its
inaugural report against the framework established by the Task
Force on Climate-related Financial Disclosures (TCFD) and now
reports against the TCFD framework annually in its Corporate
Responsibility Report. Baxter is preparing to conduct a double
materiality assessment to help evolve its approach to corporate
responsibility and ensure continued alignment with corporate
responsibility industry standards following the proposed separation
of its Kidney Care business. This includes assessing any necessary
adjustments to Baxter’s 2030 Corporate Responsibility Goals to
align with the evolving interests and makeup of the company and its
stakeholders.
Baxter furthers its aspirations as a healthcare leader by
continuing to advance efforts that demonstrate its commitment to
operating as a socially responsible and sustainable business and as
an employer of choice. Learn more about Baxter’s corporate
responsibility commitment here.
About Baxter
Every day, millions of patients, caregivers and healthcare
providers rely on Baxter’s leading portfolio of diagnostic,
critical care, kidney care, nutrition, hospital and surgical
products used across patient homes, hospitals, physician offices
and other sites of care. For more than 90 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers who make it happen.
With products, digital health solutions and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and follow us on
X/Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning
Baxter’s 2030 Corporate Responsibility Commitment and Goals and
other plans and initiatives described in the release. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: the
company’s ability to execute and complete strategic initiatives,
asset dispositions and other transactions, including the proposed
separation of the company’s Kidney Care segment; the company’s
ability to execute on its capital allocation plans (including those
with respect to Baxter’s 2023 Corporate Responsibility Commitment
and Goals); demand for and market acceptance for new and existing
products; product development risks; inability to create additional
production capacity in a timely manner or the occurrence of other
manufacturing or supply difficulties (including as a result of
natural disasters, public health crises and epidemics/pandemics,
regulatory actions or otherwise); satisfaction of regulatory and
other requirements; actions of regulatory bodies and other
governmental authorities; product quality, manufacturing or supply,
or patient safety issues; changes in law and regulations; and other
risks identified in Baxter's most recent filing on Form 10-K and
Form 10-Q and other SEC filings, all of which are available on
Baxter's website. Baxter does not undertake to update its
forward-looking statements unless otherwise required by the federal
securities laws.
Baxter is a registered trademark of Baxter International
Inc.
1 Estimated greenhouse gas emissions reductions are calculated
for the full calendar year following project implementation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240710214310/en/
Media Contact Andrea Johnson, (224) 948-5353
media@baxter.com
Investor Contact Clare Trachtman, (224) 948-3020
Grafico Azioni Baxter (NYSE:BAX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Baxter (NYSE:BAX)
Storico
Da Dic 2023 a Dic 2024